Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
By Editorial Team
Anixa Biosciences, a biotechnology company specializing in cancer treatment and prevention, has recently announced that the Korean Ministry of Intellectual Property (MOIP) has granted a Notice of Allowance for a patent related to the company's breast cancer vaccine technology. This patent, titled "Vaccine Adjuvants and Formulations," is exclusively licensed from Cleveland Clinic and aims to protect Anixa's innovative approach to breast cancer therapy and prevention in South Korea.
The co-inventors of the patent are Dr. Justin Johnson and the late Dr. Vincent Tuohy, both affiliated with Cleveland Clinic. This development marks the first Korean patent covering Anixa's breast cancer vaccine platform, expanding the company's global intellectual property coverage.
According to Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, this new patent signifies international recognition of the uniqueness and potential of their breast cancer vaccine. He emphasized that as the company progresses with clinical trials in the United States, the growing international patent portfolio strengthens their ability to pursue global opportunities and potential partnerships with major pharmaceutical companies for worldwide commercialization.
While the survival rate for breast cancer is high in South Korea, the incidence rate is rapidly increasing, particularly among younger individuals compared to Western nations. Anixa's vaccine targets human α-lactalbumin, a protein linked to certain types of breast cancer, with the goal of priming the immune system to prevent tumor development without harming normal tissue, especially in aggressive forms like triple-negative breast cancer.
Anixa's broader vaccine platform also extends to other high-incidence cancers and aims to revolutionize cancer prevention strategies. The technology, if successful, could offer one of the initial preventive vaccine approaches for breast cancer, a disease that remains the most commonly diagnosed cancer in women globally with no approved preventive vaccines currently available.
By securing a Korean patent alongside existing patents in the United States and other key markets, Anixa is strategically positioning itself for international development and commercialization endeavors. The company's collaboration with renowned research institutions like Cleveland Clinic enables continuous exploration of emerging technologies in complementary fields for further advancement and commercialization.
For more information about Anixa Biosciences and its innovative cancer treatment and prevention initiatives, visit their official website at www.anixa.com.